BACKGROUND Panitumumab, a fully human monoclonal antibody targeting epidermal growth factor receptor, is used in combination with chemotherapy for patients with metastatic colorectal cancer (mCRC). However, the effects of panitumumab in combination with irrinotecan-based chemotherapy remain uncertain. Therefore, we conducted this meta-analysis to assess the efficacy and safety of combination tr...

introduction: colo-rectal cancer has 10% prevalence, among all of the cancer proportionally and also it is the third common cancer in the both sexes. two recently introduced active drugs in the treatment of advanced colorectal cancer (acc) are irinotecan and oxaliplatin. the combinations of oxaliplatin (oxa) or irinotecan (iri) with 5fu-lv have been accepted as standard treatment for metastatic...

Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Distal recurrences represent the dominant problem with this disease. Adjuvant chemotherapy has an established benefit but the administration of highly effective chemotherapy regimens has proven difficult. In their manuscript, Barbara Jonchere and colleagues used different colon cancer cell lines with the aim to unveil novel m...